| Name | Title | Contact Details |
|---|---|---|
Luke Gordon |
Vice President of Network Development | Profile |
Using data to connect patients to therapies that better benefit them.
Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.
Mankind Pharma is one of the Indian leading pharmaceutical companies, and changes the pharma industry by providing world class medications at affordable prices and maintaining quality standards by using state-of-the-art technology for production of hig...
Academic Psychiatry is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AlgoRx Pharmaceuticals is a Wilton, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.